U.S. Stem Cell, Inc.

Climate Impact & Sustainability Data (2017-03, 2017-06-30, 2019)

The Company incurred net losses of $2,472,107 and has a working capital deficit (current liabilities in excess of current assets) of $5,895,202. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time.
Stockholders’ deficiencies at March 31, 2017 and requires additional financing to fund future operations.
The Company’s existence is dependent upon management’s ability to develop profitable operations, to obtain additional funding sources and realize revenues from the Asset Sale and Lease Agreement described herein.

The Company’s primary source of operating funds in 2016 and 2017 has been from revenue generated from sales with additional cash proceeds from the sale of common stock and the issuance of convertible and other debt.
The Company expects these conditions to improve in 2017 and beyond as it develops its business model.
The Company will continue to evaluate and act upon opportunities to increase its top line revenue position and that correspondingly increase cash in-flows. These opportunities include but are not limited to the development and marketing of new products and services, mergers and acquisitions, joint ventures, licensing deals and more.
Further, if the opportunity presents itself whereby we can raise additional capital at a reasonable fair market value, our management will do so.
Accordingly, we plan to continue in our efforts to restructure, equitize or eliminate legacy balance sheet issues that are obstacles to market capitalization appreciation and capital fund raising.

Incurred net losses of $2,896,674 and has a working capital deficit (current liabilities in excess of current assets) of $5,409,586.
Stockholders’ deficiencies at June 30, 2017 and requires additional financing to fund future operations.
Company’s existence is dependent upon management’s ability to develop profitable operations, to obtain additional funding sources and realize revenues from the Asset Sale and Lease Agreement.

The Company’s primary source of operating funds in 2016 and 2017 has been from revenue generated from sales and cash proceeds from the sale of common stock and the issuance of convertible and other debt.
expects these conditions to improve in the second half of in 2017 and beyond as it develops its business model.

Operating losses and cash outflows.
Inability to obtain sufficient capital to fund operations and expansion plans.
Difficulty building and maintaining necessary management and human resources infrastructure.
Uncertainty about the establishment of a large global market for cellular-based products and the ability to capture a meaningful market share.
Effect of U.S. Food and Drug Administration rulings, rules, and regulations.
Scientific and medical developments beyond the company's control.
Obtaining and maintaining governmental licenses, accreditations, or certifications, or complying with healthcare laws and regulations.
Securing and maintaining patent protection.
Maintaining current filings with the Securities and Exchange Commission.
Economic effects of the COVID-19 pandemic.
U.S. Food and Drug Administration injunction curtailing business.
Healthcare reform potentially reducing revenues, earnings, and cash flows.
Common stock being considered a "penny stock", making it more difficult to sell.
Weaknesses in internal controls.
Public disclosure requirements and compliance with changing regulation of corporate governance posing challenges and resulting in additional expenses.

Seeking substantial additional financing through public and/or private financing, including equity and/or debt financings, research grants, and collaborative arrangements.
Restructuring, equitizing, or eliminating legacy balance sheet issues.
Developing and marketing new products and services.
Pursuing mergers and acquisitions, joint ventures, and licensing deals.
Remediating material weaknesses in disclosure controls and procedures by hiring a full-time CFO with SEC reporting experience and expanding accounting staff.
Working with the independent registered public accounting firm to refine internal procedures.
Continuing to evaluate and act upon opportunities to increase top-line revenue and cash inflows.